BAX.N Surges Past 5-Day SMA Amid Class Action News
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 21 Nov 25
Source: Coinmarketcap
Shares of Baxter International Inc. (BAX.N) crossed above their 5-day simple moving average today, signaling a potential shift in momentum for the stock. This technical breakout comes as the company faces multiple class action lawsuits related to allegations of misleading investors about the safety of its Novum LVP devices, which reportedly suffered from systemic defects. Investors are reminded of the December 15, 2025, deadline to apply as lead plaintiffs in these lawsuits, which may have contributed to today's price action as shareholders seek to protect their interests amidst ongoing legal challenges. Analysts will be closely monitoring how these developments impact Baxter's stock performance in the coming weeks.
Analyst Views on BAX
Wall Street analysts forecast BAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BAX is 21.73 USD with a low forecast of 15.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
2 Buy
9 Hold
1 Sell
Hold
Current: 19.730
Low
15.00
Averages
21.73
High
30.00
Current: 19.730
Low
15.00
Averages
21.73
High
30.00
About BAX
Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of its sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. It provides a portfolio of diagnostic, critical care, nutrition, hospital and surgical products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
